The Biden administration has revealed the first 10 prescription drugs that will be subject to price negotiations between manufacturers and Medicare, a move aimed at making costly medications more affordable for older Americans. The drugs listed include Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara, and Fiasp and NovoLog insulins. These negotiations are part of President Biden’s efforts to tackle the rising cost of medications in the U.S. Last year’s passing of President Joe Biden’s Inflation Reduction Act, gave Medicare the power to directly negotiate drug prices. The pharmaceutical industry opposes the process, viewing it as a threat to their profits and innovation. The drug price talks are expected to save Medicare an estimated $98.5 billion over a decade and reduce the federal deficit by $237 billion over 10 years. The agreed prices for the first round of drugs will be scheduled to go into effect in 2026.